IP Library Granted Patent US 8,617,571
Granted Patent B2
US 8,617,571 · App. 12/062,372 · Granted Dec 31, 2013

Suture line administration technique using botulinum toxin

Inventor: Andrew M. Blumenfeld (Del Mar, CA)
Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,617,571
App. No.
12/062,372
Granted
Dec 31, 2013
Kind
B2
Abstract

The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.

Claims (9)

1. A method for treating a headache of a patient in need thereof, comprising the steps of:

a) determining a location of pain associated with the headache of the patient;

b) determining a location of at least one suture line of the patient that is most proximal to the location of pain, relative to other suture lines; and

c) administering a therapeutically effective amount of Clostridial neurotoxin to the patient, wherein the administration is linearly continuous and substantially superimposed along and in the vicinity of the length of at least one suture line of the patient, thereby treating the headache of the patient.

2. The method of claim 1 , wherein the Clostridial neurotoxin is a botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.

3. The method of claim 1 , wherein Clostridial neurotoxin is botulinum toxin type A.

4. The method of claim 3 , wherein the administration step includes the step of inserting a needle of a syringe containing the botulinum toxin type A at a needle penetration point, and positioning the needle along the at least one suture line so that the botulinum toxin type A is administered linearly along the at least one suture.

5. The method of claim 3 , wherein the at least one suture is selected from the group consisting of frontal suture, squamous suture, coronal suture, lambdoid suture, occipitomastoid suture and sagittal suture.

6. The method of claim 4 , further comprising the step of repositioning the needle, at the needle penetration point, to linearly deposit botulinum toxin along a second suture line.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2008
From: BLUMENFELD, ANDREW MICHAEL
To: ALLERGAN, INC.
Reel/Frame 020754/0105 →
Continuity (1)
Related Publication 20090252764A1 · Oct 8, 2009